Zacks Research Comments on Catalyst Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for shares of Catalyst Pharmaceuticals in a report issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings per share of $0.67 for the quarter, up from their prior estimate of $0.64. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.81 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2025 earnings at $0.69 EPS, Q3 2025 earnings at $0.67 EPS and FY2025 earnings at $2.70 EPS.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. The business had revenue of $110.57 million during the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%.

A number of other research analysts also recently issued reports on CPRX. TheStreet raised shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. Citigroup initiated coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, March 14th. They issued a “buy” rating and a $27.00 price target on the stock. Oppenheimer reiterated an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a report on Wednesday, March 27th. HC Wainwright restated a “buy” rating and set a $24.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. Finally, StockNews.com raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $26.43.

Catalyst Pharmaceuticals Stock Up 1.4 %

Catalyst Pharmaceuticals stock opened at $14.89 on Friday. The firm has a market cap of $1.76 billion, a P/E ratio of 24.41, a P/E/G ratio of 0.81 and a beta of 0.89. The business has a fifty day moving average of $15.54 and a two-hundred day moving average of $14.62. Catalyst Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $17.76.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new position in Catalyst Pharmaceuticals during the 3rd quarter worth approximately $502,000. Exchange Traded Concepts LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at $365,000. Handelsbanken Fonder AB increased its stake in shares of Catalyst Pharmaceuticals by 92.3% in the third quarter. Handelsbanken Fonder AB now owns 27,877 shares of the biopharmaceutical company’s stock worth $326,000 after acquiring an additional 13,377 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Catalyst Pharmaceuticals by 25.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,692 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 5,044 shares during the last quarter. Finally, Assetmark Inc. lifted its position in Catalyst Pharmaceuticals by 11.1% during the third quarter. Assetmark Inc. now owns 62,173 shares of the biopharmaceutical company’s stock valued at $727,000 after purchasing an additional 6,218 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 25,000 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $15.68, for a total value of $392,000.00. Following the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $5,470,344.32. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 12.10% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.